NCT00903630View on ClinicalTrials.gov

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Interventions
DRUG

Lenalidomide

administered by mouth at the assigned dose daily for each 28 day cycle

DRUG

liposomal doxorubicin

administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle

Trial Locations (1)

55455

University of Minnesota Medical Center - Fairview, Minneapolis

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER